Inflammatory bowel diseases: Transformation of representations. A review
- Authors: Maev I.V.1, Bakulin I.G.2, Skalinskaya M.I.2, Skazyvaeva E.V.2
-
Affiliations:
- Yevdokimov Moscow State University of Medicine and Dentistry
- Mechnikov North-Western State Medical University
- Issue: Vol 95, No 12 (2023)
- Pages: 1064-1074
- Section: Reviews
- URL: https://journals.rcsi.science/0040-3660/article/view/249440
- DOI: https://doi.org/10.26442/00403660.2023.12.202507
- ID: 249440
Cite item
Full Text
Abstract
The global burden of inflammatory bowel disease (IBD) is currently significant and continues to grow due to the increasing prevalence of ulcerative colitis (UC) and Crohn's disease (CD), the increasing costs of diagnosis and treatment, and the high level of disability in patients with this disease. Categories, which leads to the search for risk factors and predictors of aggressive course and extraintestinal manifestations. According to the latest data, the prevalence of UC in Russia is 16.6 per 100 000 population, the annual registered increase is 11.3%; the prevalence of CD is 5.6 per 100 000 population, and the increase is 13.7%. In the Russian population of patients with IBD, the average age of disease onset is 35.3 years for UC and 31.2 years for CD. Moreover, in 89.3% of patients with UC, it took at least 2 years to verify the diagnosis, and in CD, within 2 years from the onset of clinical symptoms, the diagnosis was established in only 72.6% of patients. One of the dominant characteristics of IBD is its multisystem nature, which leads to the development of extraintestinal manifestations (ECM), which can be observed in 50–60% of patients, while up to 25% of patients with IBD have several EMC and the most common variants are joint lesions. A higher frequency of extraintestinal manifestations is observed in CD (up to 45% of patients), in female patients, in smokers and with a longer duration of the disease. To predict clinical remission, the level of fecal calprotectin and CRP, the need for glucocorticosteroids are important, to predict endoscopic remission – the level of fecal calprotectin, and to predict histological remission, an endoscopic Schroeder index value of ≤1 is important. The absolute risk of developing colorectal cancer in IBD remains relatively low, ranging from 1.1 to 5.4% after 20 years of disease. The main risk factors for IBD are total intestinal damage, high inflammatory activity, the stricturing phenotype of CD and the presence of primary sclerosing cholangitis.
Full Text
##article.viewOnOriginalSite##About the authors
Igor V. Maev
Yevdokimov Moscow State University of Medicine and Dentistry
Author for correspondence.
Email: igormaev@rambler.ru
ORCID iD: 0000-0001-6114-564X
акад. РАН, доктор медицинских наук, профессор, зав. кафедрой пропедевтики внутренних болезней и гастроэнтерологии
Russian Federation, MoscowIgor G. Bakulin
Mechnikov North-Western State Medical University
Email: igormaev@rambler.ru
ORCID iD: 0000-0002-6151-2021
доктор медицинских наук, профессор, зав. кафедрой пропедевтики внутренних болезней, гастроэнтерологии и диетологии
Russian Federation, Saint PetersburgMaria I. Skalinskaya
Mechnikov North-Western State Medical University
Email: igormaev@rambler.ru
ORCID iD: 0000-0003-0769-8176
кандидат медицинских наук, доц. каф. пропедевтики внутренних болезней, гастроэнтерологии и диетологии
Russian Federation, Saint PetersburgEkaterina V. Skazyvaeva
Mechnikov North-Western State Medical University
Email: igormaev@rambler.ru
ORCID iD: 0000-0002-8563-6870
кандидат медицинских наук, доцент каф. пропедевтики внутренних болезней, гастроэнтерологии и диетологии
Russian Federation, Saint PetersburgReferences
- Белоусова Е.А., Шелыгин Ю.А., Ачкасов С.И., и др. Клинико-демографические характеристики и лечебные подходы у пациентов с воспалительными заболеваниями кишечника (болезнь Крона, язвенный колит) в РФ. Первые результаты анализа национального регистра. Колопроктология. 2023;1(83):65-82 [Belousova EA, Shelygin YuA, Achkasov SI, et al. Clinical and demographic features and treatment approaches for inflammatory bowel diseases (Crohn’s disease, ulcerative colitis) in the Russia. The primery results of the analysis of the National Register. Koloproktologia. 2023;22(1):65-82 (in Russian)]. doi: 10.33878/2073-7556-2023-22-1-65-82
- GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(1):17-30. doi: 10.1016/S2468-1253(19)30333-4
- Kaplan GG, Ng SC. Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology. 2017;152(2):313-21.e2. doi: 10.1053/j.gastro.2016.10.020
- Hammer T, Langholz E. The epidemiology of inflammatory bowel disease: Balance between East and West? A narrative review. Dig Med Res. 2020;3:48. doi: 10.21037/dmr-20-149
- Burisch J, Jess T, Martinato M, Lakatos PL; ECCO-EpiCom. The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013;7(4):322-37. doi: 10.1016/j.crohns.2013.01.010
- Coward S, Clement F, Benchimol EI, et al. Past and future burden of inflammatory bowel diseases based on modeling of population-based data. Gastroenterology. 2019;156(5):1345-53.e4. doi: 10.1053/j.gastro.2019.01.002
- Ghione S, Sarter H, Fumery M, et al. Dramatic Increase in Incidence of Ulcerative Colitis and Crohn's Disease (1988–2011): A Population-Based Study of French Adolescents. Am J Gastroenterol. 2018;113(2):265-272. doi: 10.1038/ajg.2017.228
- van den Heuvel TRA, Jeuring SFG, Zeegers MP, et al. A 20-Year temporal change analysis in incidence, presenting phenotype and mortality, in the dutch IBDSL cohort-can diagnostic factors explain the increase in IBD incidence? J Crohns Colitis. 2017;11(10):1169-79. doi: 10.1093/ecco-jcc/jjx055
- Murakami Y, Nishiwaki Y, Oba MS, et al. Estimated prevalence of ulcerative colitis and Crohn's disease in Japan in 2014: An analysis of a nationwide survey. J Gastroenterol. 2019;54(12):1070-7. doi: 10.1007/s00535-019-01603-8
- Kim HJ, Hann HJ, Hong SN, et al. Incidence and natural course of inflammatory bowel disease in Korea, 2006–2012: A nationwide population-based study. Inflamm Bowel Dis. 2015;21(3):623-30. doi: 10.1097/MIB.0000000000000313
- Ng SC, Tang W, Ching JY, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-Pacific Crohn's and colitis epidemiology study. Gastroenterology. 2013;145(1):158-165.e2. doi: 10.1053/j.gastro.2013.04.007
- Ng SC, Kaplan GG, Tang W, et al. Population density and risk of inflammatory bowel disease: A prospective population-based study in 13 countries or regions in Asia-Pacific. Am J Gastroenterol. 2019;114(1):107-15. doi: 10.1038/s41395-018-0233-2
- Князев О.В., Шкурко Т.В., Фадеева Н.А., и др. Эпидемиология хронических воспалительных заболеваний кишечника. Вчера, сегодня, завтра. Экспериментальная и клиническая гастроэнтерология. 2017;3(139):4-12 [Knyazev OV, Shkurko TV, Fadeyeva NA, et al. Epidemiology of chronic inflammatory bowel disease. Yesterday, today, tomorrow. Eksperimental’naya i Klinicheskaya Gastroenterologiya. 2017;3(139):4-12 (in Russian)].
- Белоусова Е.А., Халиф И.Л., Абдулганиева Д.И., и др. Социально-демографическая характеристика, особенности течения и варианты лечения воспалительных заболеваний кишечника в России. Результаты двух многоцентровых исследований. Альманах клинической медицины. 2018;46(5):445-63 [Belousova EA, Halif IL, Abdulganieva DI, et al. Social and demographic characteristics, features of disease course and treatment options of inflammatory bower disease in Russia: Results of two multicenter studies. Almanac of Clinical Medicine. 2018;46(5):445-63 (in Russian)]. doi: 10.18786/2072-0505-2018-46-5-445-463
- Князев О.В., Белоусова Е.А., Абдулганиева Д.И., и др. Реальная практика лекарственной терапии среднетяжелых и тяжелых форм воспалительных заболеваний кишечника в России, Республике Беларусь и Республике Казахстан. Промежуточные результаты исследования INTENT. Альманах клинической медицины. 2021;49(7):443-54 [Knyazev OV, Belousova EA, Abdulganieva DI, et al. Real world practice of medical treatment for moderate and severe inflammatory bowel diseases in Russian Federation, Republic of Belarus and Republic of Kazakhstan: Intermediate results of the INTENT study. Almanac of Clinical Medicine. 2021;49(7):443-54 (in Russian)]. doi: 10.18786/2072-0505-2021-49-061
- Kaplan GG, Ng SC. Globalisation of inflammatory bowel disease: perspectives from the evolution of inflammatory bowel disease in the UK and China. Lancet Gastroenterol Hepatol. 2016;1(4):307-16. doi: 10.1016/S2468-1253(16)30077-2
- Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46-54.e42; quiz e30. doi: 10.1053/j.gastro.2011.10.001
- Rogler G, Biedermann L, Scharl M. New insights into the pathophysiology of inflammatory bowel disease: Microbiota, epigenetics and common signalling pathways. Swiss Med Wkly. 2018;148:w14599. doi: 10.4414/smw.2018.14599
- Piovani D, Danese S, Peyrin-Biroulet L, et al. Environmental risk factors for inflammatory bowel diseases: An umbrella review of meta-analyses. Gastroenterology. 2019;157(3):647-659.e4. doi: 10.1053/j.gastro.2019.04.016
- Thomas T, Chandan JS, Li VSW, et al. Global smoking trends in inflammatory bowel disease: A systematic review of inception cohorts. PLoS One. 2019;14(9):e0221961. doi: 10.1371/journal.pone.0221961
- Ng SC, Tang W, Leong RW, et al. Environmental risk factors in inflammatory bowel disease: A population-based case-control study in Asia-Pacific. Gut. 2015;64(7):1063-71. doi: 10.1136/gutjnl-2014-307410
- Cui G, Yuan A. A systematic review of epidemiology and risk factors associated with Chinese inflammatory bowel disease. Front Med (Lausanne). 2018;5:183. doi: 10.3389/fmed.2018.00183
- Altajar S, Moss A. Inflammatory bowel disease environmental risk factors: Diet and gut microbiota. Curr Gastroenterol Rep. 2020;22(12):57. doi: 10.1007/s11894-020-00794-y
- Mak WY, Zhao M, Ng SC, Burisch J. The epidemiology of inflammatory bowel disease: East meets west. J Gastroenterol Hepatol. 2020;35(3):380-9. doi: 10.1111/jgh.14872
- Hviid A, Svanström H, Frisch M. Antibiotic use and inflammatory bowel diseases in childhood. Gut. 2011;60(1):49-54. doi: 10.1136/gut.2010.219683
- Ungaro R, Bernstein CN, Gearry R, et al. Antibiotics associated with increased risk of new-onset Crohn's disease but not ulcerative colitis: A meta-analysis. Am J Gastroenterol. 2014;109(11):1728-38. doi: 10.1038/ajg.2014.246
- Rosen MJ, Dhawan A, Saeed SA. Inflammatory bowel disease in children and adolescents. JAMA Pediatr. 2015;169(11):1053-60. doi: 10.1001/jamapediatrics.2015.1982
- Sýkora J, Pomahačová R, Kreslová M, et al. Current global trends in the incidence of pediatric-onset inflammatory bowel disease. World J Gastroenterol. 2018;24(25):2741-63. doi: 10.3748/wjg.v24.i25.2741
- Kuenzig ME, Fung SG, Marderfeld L, et al. Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease: Systematic review. Gastroenterology. 2022;162(4):1147-59.e4. doi: 10.1053/j.gastro.2021.12.282
- Lakatos L, Kiss LS, David G, et al. Incidence, disease phenotype at diagnosis, and early disease course in inflammatory bowel diseases in Western Hungary, 2002–2006. Inflamm Bowel Dis. 2011;17(12):2558-65. doi: 10.1002/ibd.21607
- Rönnblom A, Holmström T, Tanghöj H, et al. Low colectomy rate five years after diagnosis of ulcerative colitis. Results from a prospective population-based cohort in Sweden (ICURE) diagnosed during 2005–2009. Scand J Gastroenterol. 2016;51(11):1339-44. doi: 10.1080/00365521.2016.1200141
- Su HY, Gupta V, Day AS, Gearry RB. Rising incidence of inflammatory bowel disease in Canterbury, New Zealand. Inflamm Bowel Dis. 2016;22(9):2238-44. doi: 10.1097/MIB.0000000000000829
- Шелыгин Ю.А., Ивашкин В.Т., Ачкасов С.И., и др. Клинические рекомендации. Болезнь Крона (К50), взрослые. Колопроктология. 2023;3(85):10-49 [Shelygin YA, Ivashkin VT, Achkasov SI, et al. Clinical guidelines. Crohn’s disease (К50), adults. Koloproktologia. 2023;22(3):10-49 (in Russian)]. doi: 10.33878/2073-7556-2023-22-3-10-49
- Бакулин И.Г., Жигалова Т.Н., Латария Э.Л., и др. Опыт внедрения Федерального регистра пациентов с воспалительными заболеваниями кишечника в Санкт-Петербурге. Фарматека. 2017;S5:56-9 [Bakulin IG, Zhigalova TN, Latariya EL, et al. Experience of introduction of the Federal Registry of patients with inflammatory bowel diseases in Saint Petersburg. Pharmateca. 2017;S5:56-9 (in Russian)].
- Бакулин И.Г., Скалинская М.И., Сказываева Е.В. Северо-Западный регистр пациентов с воспалительными заболеваниями кишечника: достижения и уроки. Колопроктология. 2022;21(1):37-49 [Bakulin IG, Skalinskaya MI, Skazyvaeva EV. North-Western register of patients with inflammatory bowel diseases: Achievements and lessons learned. Koloproktologia. 2022;21(1):37-49 (in Russian)]. doi: 10.33878/2073-7556-2022-21-1-37-49
- Маев И.В., Шелыгин Ю.А., Скалинская М.И., и др. Патоморфоз воспалительных заболеваний кишечника. Вестник Российской академии медицинских наук. 2020;75(1):27-35 [Maev IV, Shelygin YuA, Skalinskaya MI, et al. The pathomorphosis of inflammatory bowel diseases. Annals of the Russian Academy of Medical Sciences. 2020;75(1):27-35 (in Russian)]. doi: 10.15690/vramn1219
- Шелыгин Ю.А., Ивашкин В.Т., Белоусова Е.А., и др. Язвенный колит (К51), взрослые. Колопроктология. 2023;22(1):10-44 [Shelygin YuA, Ivashkin VT, Belousova EA, et al. Ulcerative colitis (K51), adults. Koloproktologia. 2023;22(1):10-44 (in Russian)]. doi: 10.33878/2073-7556-2023-22-1-10-44
- Burisch J, Katsanos KH, Christodoulou DK, et al. Natural disease course of ulcerative colitis during the first five years of follow-up in a European population-based inception cohort-an Epi-IBD study. J Crohns Colitis. 2019;13(2):198-208. doi: 10.1093/ecco-jcc/jjy154
- Dragasevic S, Sokic-Milutinovic A, Stojkovic Lalosevic M, et al. Correlation of Patient-Reported Outcome (PRO-2) with endoscopic and histological features in ulcerative colitis and Crohn's disease patients. Gastroenterol Res Pract. 2020;2020:2065383. doi: 10.1155/2020/2065383
- Wong D, Travis SPL. Patient-reported goals in inflammatory bowel disease: What's the problem? J Crohns Colitis. 2022;16(3):339-40. doi: 10.1093/ecco-jcc/jjab156
- Irving P, Burisch J, Driscoll R, et al. IBD2020 global forum: Results of an international patient survey on quality of care. Intest Res. 2018;16(4):537-45. doi: 10.5217/ir.2018.00041
- Fairbrass KM, Costantino SJ, Gracie DJ, Ford AC. Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(12):1053-62. doi: 10.1016/S2468-1253(20)30300-9
- Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021;18(1):56-66. doi: 10.1038/s41575-020-00360-x
- Ananthakrishnan AN, Kaplan GG, Ng SC. Changing global epidemiology of inflammatory bowel diseases: Sustaining health care delivery into the 21st century. Clin Gastroenterol Hepatol. 2020;18(6):1252-60. doi: 10.1016/j.cgh.2020.01.028
- Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies [published correction appears in Lancet. 2020 Oct 3;396(10256):e56]. Lancet. 2017;390(10114):2769-78. doi: 10.1016/S0140-6736(17)32448-0
- Buie MJ, Quan J, Windsor JW, et al. Global hospitalization trends for Crohn's disease and ulcerative colitis in the 21st century: A systematic review with temporal analyses. Clin Gastroenterol Hepatol. 2023;21(9):2211-21. doi: 10.1016/j.cgh.2022.06.030
- Viscido A, Papi C, Latella G, Frieri G. Has infliximab influenced the course and prognosis of acute severe ulcerative colitis? Biologics. 2019;13:23-31. doi: 10.2147/BTT.S179006
- Candido FD, Fiorino G, Spadaccini M, et al. Are surgical rates decreasing in the biological era in IBD? Curr Drug Targets. 2019;20(13):1356-62. doi: 10.2174/1389450120666190426165325
- Dheri AK, Kuenzig ME, Mack DR, et al. Shifting health care use from hospitalisations and surgeries to outpatient visits in children with inflammatory bowel disease: A population-based cohort study from Ontario, Canada. J Crohns Colitis. 2021;15(12):1991-2000. doi: 10.1093/ecco-jcc/jjab095
- Walldorf J, Twarz M, Schober C, et al. High frequency of secondary, but not primary ocular manifestations of inflammatory bowel disease in patients treated at a tertiary care center. Eur J Gastroenterol Hepatol. 2018;30(12):1502-6. doi: 10.1097/MEG.0000000000001248
- Karmiris K, Avgerinos A, Tavernaraki A, et al. Prevalence and characteristics of extra-intestinal manifestations in a large cohort of Greek patients with inflammatory bowel disease. J Crohns Colitis. 2016;10(4):429-36. doi: 10.1093/ecco-jcc/jjv232
- Bernstein CN, Blanchard JF, Rawsthorne P, et al. The prevalence of extraintestinal diseases in inflammatory bowel disease: A population-based study. Am J Gastroenterol. 2001;96(4):1116-22. doi: 10.1111/j.1572-0241.2001.03756.x
- van Erp SJ, Brakenhoff LK, van Gaalen FA, et al. Classifying back pain and peripheral joint complaints in inflammatory bowel disease patients: A prospective longitudinal follow-up study. J Crohns Colitis. 2016;10(2):166-75. doi: 10.1093/ecco-jcc/jjv195
- Severs M, Spekhorst LM, Mangen MJ, et al. Sex-related differences in patients with inflammatory bowel disease: Results of 2 prospective cohort studies. Inflamm Bowel Dis. 2018;24(6):1298-306. doi: 10.1093/ibd/izy004
- Roth N, Biedermann L, Fournier N, et al. Occurrence of skin manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study. PLoS One. 2019;14(1):e0210436. doi: 10.1371/journal.pone.0210436
- Vavricka SR, Rogler G, Gantenbein C, et al. Chronological order of appearance of extraintestinal manifestations relative to the time of IBD diagnosis in the Swiss Inflammatory Bowel Disease Cohort. Inflamm Bowel Dis. 2015;21(8):1794-800. doi: 10.1097/MIB.0000000000000429
- Sepriano A, Rubio R, Ramiro S, et al. Performance of the ASAS classification criteria for axial and peripheral spondyloarthritis: A systematic literature review and meta-analysis. Ann Rheum Dis. 2017;76(5):886-90. doi: 10.1136/annrheumdis-2016-210747
- Vavricka SR, Brun L, Ballabeni P, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011;106(1):110-19. doi: 10.1038/ajg.2010.343
- Yadav S, Singh S, Edakkanambeth Varayil J, et al. Hidradenitis suppurativa in patients with inflammatory bowel disease: A population-based cohort study in Olmsted County, Minnesota. Clin Gastroenterol Hepatol. 2016;14(1):65-70. doi: 10.1016/j.cgh.2015.04.173
- Gordon H, Burisch J, Ellul P, et al. ECCO Guidelines on Extraintestinal Manifestations in Inflammatory Bowel Disease. J Crohns Colitis. 2023;jjad108. doi: 10.1093/ecco-jcc/jjad108
- Lauritano D, Boccalari E, Di Stasio D, et al. Prevalence of oral lesions and correlation with intestinal symptoms of inflammatory bowel disease: A systematic review. Diagnostics (Basel). 2019;9(3):77. doi: 10.3390/diagnostics9030077
- Ribaldone DG, Brigo S, Mangia M, et al. Oral manifestations of inflammatory bowel disease and the role of non-invasive surrogate markers of disease activity. Medicines (Basel). 2020;7(6):33. doi: 10.3390/medicines7060033
- Durgin JS, Rodriguez O, Sollecito T, et al. Diagnosis, clinical features, and management of patients with granulomatous cheilitis. JAMA Dermatol. 2021;157(1):112-4. doi: 10.1001/jamadermatol.2020.4383
- Benjaminsen E, Myhr KM, Grytten N, Alstadhaug KB. Comorbidity in multiple sclerosis patients from Nordland County, Norway – validated data from the Norwegian Patient Registry. Mult Scler Relat Disord. 2021;48:102691. doi: 10.1016/j.msard.2020.102691
- Chen M, Lee G, Kwong LN, et al. Cerebral white matter lesions in patients with Crohn's disease. J Neuroimaging. 2012;22(1):38-41. doi: 10.1111/j.1552-6569.2010.00538.x
- Moisset X, Bommelaer G, Boube M, et al. Migraine prevalence in inflammatory bowel disease patients: A tertiary-care centre cross-sectional study. Eur J Pain. 2017;21(9):1550-60. doi: 10.1002/ejp.1056
- Goolsby TA, Jakeman B, Gaynes RP. Clinical relevance of metronidazole and peripheral neuropathy: A systematic review of the literature. Int J Antimicrob Agents. 2018;51(3):319-25. doi: 10.1016/j.ijantimicag.2017.08.033
- Fromont A, De Seze J, Fleury MC, et al. Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. Cytokine. 2009;45(2):55-7. doi: 10.1016/j.cyto.2008.11.002
- Beheshti Maal A, Shahrbaf MA, Sadri B, et al. Prevalence of hepatobiliary manifestations in inflammatory bowel disease: A GRADE assessed systematic review and meta-analysis on more than 1.7 million patients. J Crohns Colitis. 2023:jjad157. doi: 10.1093/ecco-jcc/jjad157
- Saich R, Chapman R. Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease. World J Gastroenterol. 2008;14(3):331-7. doi: 10.3748/wjg.14.331
- Palmela C, Peerani F, Castaneda D, et al. Inflammatory bowel disease and primary sclerosing cholangitis: A review of the phenotype and associated specific features. Gut Liver. 2018;12(1):17-29. doi: 10.5009/gnl16510
- Rocha HC, Vilela EG. Clinical aspects and prognosis of patients with inflammatory bowel disease associated with autoimmune liver diseases. Gastroenterol Hepatol. 2022;45(2):83-90. doi: 10.1016/j.gastrohep.2021.03.011
- Barberio B, Massimi D, Cazzagon N, et al. Prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease: A systematic review and meta-analysis. Gastroenterology. 2021;161(6):1865-77. doi: 10.1053/j.gastro.2021.08.032
- Zamani M, Alizadeh-Tabari S, Singh S, et al. Meta-analysis: Prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2022;55(8):894-907. doi: 10.1111/apt.16879
- Eliadou E, Moleiro J, Ribaldone DG, et al. Interstitial and granulomatous lung disease in inflammatory bowel disease patients. J Crohns Colitis. 2020;14(4):480-9. doi: 10.1093/ecco-jcc/jjz165
- Harbord M, Annese V, Vavricka SR, et al. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016;10(3):239-54. doi: 10.1093/ecco-jcc/jjv213
- Sinagra E, Aragona E, Romano C, et al. The role of portal vein thrombosis in the clinical course of inflammatory bowel diseases: Report on three cases and review of the literature. Gastroenterol Res Pract. 2012;2012:916428. doi: 10.1155/2012/916428
- Скалинская М.И., Деев Р.В., Пресняков Е.В., и др. Гистион эпителиального кишечного барьера при воспалительных заболеваниях кишечника: морфофункциональная характеристика и клиническое значение. РМЖ. Медицинское обозрение. 2023;7(5):292-9 [Skalinskaya MI, Deev RV, Presnyakov EV, et al. Histione of the intestinal epithelial barrier in inflammatory bowel diseases: Morphofunctional characteristics and clinical significance. Russian Medical Inquiry. 2023;7(5):292-9 (in Russian)]. doi: 10.32364/2587-6821-2023-7-5-7
- Park J, Kang SJ, Yoon H, et al. Histologic evaluation using the robarts histopathology index in patients with ulcerative colitis in deep remission and the association of histologic remission with risk of relapse. Inflamm Bowel Dis. 2022;28(11):1709-16. doi: 10.1093/ibd/izab340
- Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: An update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570-83. doi: 10.1053/j.gastro.2020.12.031
- Kirchgesner J, Svrcek M, Le Gall G, et al. Nancy index scores of chronic inflammatory bowel disease activity associate with development of colorectal neoplasia. Clin Gastroenterol Hepatol. 2020;18:150-7.e1. doi: 10.1016/j.cgh.2019.05.002
- Yoon H, Jangi S, Dulai PS, et al. Incremental benefit of achieving endoscopic and histologic remission in patients with ulcerative colitis: A systematic review and meta-analysis. Gastroenterology. 2020;159:1262-75.e7. doi: 10.1053/j.gastro.2020.06.043
- Danese S, Roda G, Peyrin-Biroulet L. Evolving therapeutic goals in ulcerative colitis: Towards disease clearance. Nat Rev Gastroenterol Hepatol. 2020;17(1):1-2. doi: 10.1038/s41575-019-0211-1
- Ernández-Rocha C, Nayeri S, Turpin W, et al. Combined histo-endoscopic remission but not endoscopic healing alone in ulcerative colitis is associated with a mucosal transcriptional profile resembling healthy mucosa. J Crohn’s Colitis. 2022;16:1020-9. doi: 10.1093/ecco-jcc/jjac001
- Manuc M, Ionescu EM, Milanesi E, et al. Molecular signature of persistent histological inflammation in ulcerative colitis with mucosal healing. J Gastrointestin Liver Dis. 2020;29(2):159-66. doi: 10.15403/jgld-576
- Ho GT, Chiam P, Drummond H, et al. The efficacy of corticosteroid therapy in inflammatory bowel disease: Analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther. 2006;24(2):319-30. doi: 10.1111/j.1365-2036.2006.02974.x
- Singeap AM, Girleanu I, Diculescu M, et al. Risk factors for extraintestinal manifestations in inflammatory bowel diseases – data from the Romanian National Registry. J Gastrointestin Liver Dis. 2021;30(3):346-57. doi: 10.15403/jgld-3818
- Wang Z, Zhang H, Yang H, et al. The incidence rate and risk factors of malignancy in elderly-onset inflammatory bowel disease: A Chinese Cohort Study From 1998 to 2020. Front Oncol. 2021;11:788980. doi: 10.3389/fonc.2021.788980
- Huai JP, Ding J, Ye XH, et al. Inflammatory bowel disease and risk of cholangiocarcinoma: Evidence from a meta-analysis of population-based studies. Asian Pac J Cancer Prev. 2014;15(8):3477-82. doi: 10.7314/apjcp.2014.15.8.3477
- Trivedi PJ, Crothers H, Mytton J, et al. Effects of primary sclerosing cholangitis on risks of cancer and death in people with inflammatory bowel disease, based on sex, race, and age. Gastroenterology. 2020;159(3):915-28. doi: 10.1053/j.gastro.2020.05.049
- Jung YS, Han M, Park S, et al. Cancer risk in the early stages of inflammatory bowel disease in Korean patients: A Nationwide Population-based Study. J Crohns Colitis. 2017;11(8):954-62. doi: 10.1093/ecco-jcc/jjx040
- Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: A meta-analysis. Gut. 2001;48(4):526-35. doi: 10.1136/gut.48.4.526
- Dai N, Haidar O, Askari A, et al. Colectomy rates in ulcerative colitis: A systematic review and meta-analysis. Dig Liver Dis. 2023;55(1):13-20. doi: 10.1016/j.dld.2022.08.039
- Fradet C, Kern J, Atanasov P, et al. Impact of surgery and its complications in ulcerative colitis patients in clinical practice: A systematic literature review of real-world evidence in Europe. Int J Surg Open. 2019;22:22-32. doi: 10.1016/j.ijso.2019.11.010
- Lu C, Schardey J, Zhang T, et al. Survival outcomes and clinicopathological features in inflammatory bowel disease-associated colorectal cancer: A systematic review and meta-analysis. Ann Surg. 2022;276(5):e319-30. doi: 10.1097/SLA.0000000000005339
- Everhov ÅH, Erichsen R, Sachs MC, et al. Inflammatory bowel disease and pancreatic cancer: A Scandinavian Register-Based Cohort Study 1969–2017. Aliment Pharmacol Ther. 2020;52(1):143-54. doi: 10.1111/apt.15785
- Yuan F, Pfeiffer RM, Julián-Serrano S, et al. Autoimmune conditions and pancreatic cancer risk in older American adults. Int J Cancer. 2023;152(2):172-82. doi: 10.1002/ijc.34235
- Massano A, Bertin L, Zingone F, et al. Extraintestinal cancers in inflammatory bowel disease: A literature review. Cancers. 2023;15(15):3824. doi: 10.3390/cancers15153824
- Lo B, Zhao M, Vind I, Burisch J. The risk of extraintestinal cancer in inflammatory bowel disease: A systematic review and meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2021;19(6):1117-38.e19. doi: 10.1016/j.cgh.2020.08.015
- Russo MF, Diddoro A, Iodice A, et al. Incidence of lymphomas in inflammatory bowel disease: Report of an emblematic case, systematic review, and meta-analysis. Front Med. 2023;10:1172634. doi: 10.3389/fmed.2023.1172634
- Bernstein CN, Nabalamba A. Hospitalization, surgery, and readmission rates of IBD in Canada: A population-based study. Am J Gastroenterol. 2006;101(1):110-18. doi: 10.1111/j.1572-0241.2006.00330.x
- Pavel C, Diculescu M, Constantinescu G, et al. Surgery for inflammatory bowel disease in the era of biologic therapy: A multicenter experience from Romania. Medicina (Kaunas). 2023;59(2):337. doi: 10.3390/medicina59020337
- King D, Rees J, Mytton J, et al. The outcomes of emergency admissions with ulcerative colitis between 2007 and 2017 in England. J Crohn’s Colitis. 2020;14(6):764-72. doi: 10.1093/ecco-jcc/jjz185
- Chaparro A, Garre A, Ortiz AN, et al. Incidence, clinical characteristics and management of inflammatory bowel disease in Spain: Large-Scale Epidemiological Study. J Clin Med. 2021;10(13):2885. doi: 10.3390/jcm10132885
- Zaharie R, Tantau A, Zaharie F. Diagnostic delay in Romanian patients with inflammatory bowel disease: Risk factors and impact on the disease course and need for surgery. J Crohn’s Colitis. 2015;10(3):306-14. doi: 10.1093/ecco-jcc/jjv215
- Lowe SC, Sauk JS, Limketkai BN, Kwaan MR. Declining rates of surgery for inflammatory bowel disease in the era of biologic therapy. J Gastrointest Surg. 2021;25(1):211-9. doi: 10.1007/s11605-020-04832-y
![](/img/style/loading.gif)